Inventor
HARIPRASAD VANKAYALAPATI
Inventor
US
Overview
Patents· 4 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds36%
A61KPreparations for medical, dental or toiletry purposes27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium9%
PatentTitleYear
12,595,273Phosphonate conjugates and uses thereof202612,275,738CDK9 inhibitors202511,407,729Quinoline and quinazoline compounds and methods of use thereof202211,142,524Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2022Patents assigned to STINGRAY THERAPEUTICS INC (2)· patent assignee history
2021–2026Based in US· patent location history
2025Patents assigned to BIOLEXIS THERAPEUTICS INC (1)· patent assignee history
2026Patents assigned to THE TRANSLATIONAL GENOMICS RES INSTITUTE (1)· patent assignee history
2026Patents assigned to UNIV OF UTAH RESEARCH FOUNDATION (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| STINGRAY THERAPEUTICS INC | 2 | 2021–2022 |
| BIOLEXIS THERAPEUTICS INC | 1 | 2025 |
| THE TRANSLATIONAL GENOMICS RES INSTITUTE | 1 | 2026 |
| UNIV OF UTAH RESEARCH FOUNDATION | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 4 | 2021–2026 |